Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VKTX Stock Price Chart Interactive Chart >
VKTX Price/Volume Stats
|Current price||$2.71||52-week high||$7.20|
|Prev. close||$2.80||52-week low||$2.02|
|Day high||$2.82||Avg. volume||1,119,661|
|50-day MA||$2.37||Dividend yield||N/A|
|200-day MA||$4.10||Market Cap||209.68M|
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Most Popular Stories View All
VKTX Latest News Stream
|Loading, please wait...|
VKTX Latest Social Stream
View Full VKTX Social Stream
Latest VKTX News From Around the Web
Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $10.00. The company's shares closed last Thursday at $4.05, close to its 52-week low of $3.22. According to TipRanks.com, Rahman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.2% and a 11.5% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Vertex Pharmaceuticals, and Galmed Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $19.
The stock market is giving investors some real healthcare bargains right now. Patrick Bafuma (Intercept Pharma): I will freely admit that Intercept Pharma has been a dog through the years, down a maddening 87% over the last five years. A significant portion of Intercept's drop was also due to a complete response letter in June 2020 for the treatment of non-alcoholic steatohepatitis (NASH).
Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 9, 2022, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines, and milestones.
Viking Therapeutics press release (NASDAQ:VKTX): Q4 GAAP EPS of -$0.16 beats by $0.03....
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments.
VKTX Price Returns